July 30, 2020
Tokyo based biotech Healios said on July 29 that it has started enrolling patients with acute respiratory distress syndrome (ARDS) induced by COVID-19 pneumonia into its ongoing Japan PII study for the investigational off-the-shelf somatic stem cell therapy HLCM051. Healios...read more